You just read:

Ibrutinib (IMBRUVICA®) Supplemental New Drug Application Submitted to the U.S. Food and Drug Administration (FDA) for Marginal Zone Lymphoma (MZL)

News provided by

Janssen Pharmaceutical Companies

Sep 26, 2016, 07:30 ET